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Accompanying Appendix S1, which lists the members of the China PEACE‐Retrospective AMI Study Site Investigators by Hospital and China PEACE Study Consultants, Tables S1 through S3, Figure S1, and Data S1 are available at <http://jaha.ahajournals.org/content/5/2/e003012/suppl/DC1>

Introduction {#jah31324-sec-0005}
============

As part of China\'s epidemiologic transition to higher rates of noncommunicable diseases, women, like men, are experiencing a rapid increase in the incidence of acute myocardial infarction (AMI) and AMI‐related mortality,[1](#jah31324-bib-0001){ref-type="ref"} as seen in other low‐ and middle‐income countries.[2](#jah31324-bib-0002){ref-type="ref"} In addition, the China Patient‐centered Evaluative Assessment of Cardiac Events (PEACE) study demonstrated sex differences in mortality with women at higher risk of death in younger age groups.[3](#jah31324-bib-0003){ref-type="ref"} Yet, much less is known about whether sex differences in clinical profiles and care quality differ between men and women and, if so, whether these differences are explained by age, and how they change over time.

Understanding sex differences in the clinical presentation and quality of care for high‐impact conditions like AMI is instrumental to the prioritization of resources for quality improvement programs. A recognition of sex differences in the treatment of myocardial infarction in the late 1990s and early 2000s[4](#jah31324-bib-0004){ref-type="ref"}, [5](#jah31324-bib-0005){ref-type="ref"}, [6](#jah31324-bib-0006){ref-type="ref"} in the United States led to national campaigns[7](#jah31324-bib-0007){ref-type="ref"} and female‐specific guidelines.[8](#jah31324-bib-0008){ref-type="ref"}, [9](#jah31324-bib-0009){ref-type="ref"}, [10](#jah31324-bib-0010){ref-type="ref"} Subsequently, sex gaps in care have narrowed over time.[5](#jah31324-bib-0005){ref-type="ref"}, [11](#jah31324-bib-0011){ref-type="ref"} Previous studies in China demonstrate similar sex differences in treatment of comorbidities and outcomes.[3](#jah31324-bib-0003){ref-type="ref"}, [12](#jah31324-bib-0012){ref-type="ref"}, [13](#jah31324-bib-0013){ref-type="ref"}, [14](#jah31324-bib-0014){ref-type="ref"} However, these studies were generally limited to single sites or centers located predominantly in urban areas and examined single points in time, warranting a national perspective on sex differences in clinical presentation and quality of care in China.[12](#jah31324-bib-0012){ref-type="ref"}, [13](#jah31324-bib-0013){ref-type="ref"} Moreover, given that women are older than men at the time of an AMI,[3](#jah31324-bib-0003){ref-type="ref"}, [15](#jah31324-bib-0015){ref-type="ref"} it remains unknown whether these differences could be explained by age or how sex‐based differences have changed over the last decade during improved access and healthcare quality in China.[16](#jah31324-bib-0016){ref-type="ref"}

To provide insights into differences in patient characteristics and quality of care over time between men and women, we analyzed data from the China PEACE Retrospective AMI Study,[17](#jah31324-bib-0017){ref-type="ref"} which included a random nationally representative sample of patients with AMI from 63 urban and 99 rural hospitals across China in 2001, 2006, and 2011. We have previously shown women in the younger age group had higher in‐hospital mortality. In this study, our primary aim is to investigate sex differences in the presenting characteristics and quality of care of patients with ST‐segment elevation myocardial infarction (STEMI), whether these differences could be accounted for by age, and to examine temporal trends.

Methods {#jah31324-sec-0006}
=======

Study Design {#jah31324-sec-0007}
------------

The objectives, scope, and purpose of the China PEACE Retrospective AMI Study have been described previously.[17](#jah31324-bib-0017){ref-type="ref"} In brief, using 2‐stage random sampling, a nationally representative sample of patients admitted with AMI in 2001, 2006, and 2011 was obtained. We stratified the hospitals into 5 economic--geographical regions (eastern rural, central rural, western rural, eastern urban, and central--western urban) since hospital volumes and clinical capacities differ between urban and rural areas and between the 3 official economic--geographical regions (eastern, central, and western) of China. We used systematic random sampling procedures to select patients with AMI from the local hospital database of each sampled hospital in each study year. We used version 9 (410.xx) and version 10 (I21.xx; when available) ICD codes to screen for possible cases of AMI. These cases were then further confirmed by clinical record assessment. Detailed clinical data were then collected by data abstraction to identify those cases that represented initial AMI episodes according to the definition in the 2010 China National Guideline for STEMI.[18](#jah31324-bib-0018){ref-type="ref"} The central ethics committee at the National Center for Cardiovascular Diseases approved the study. All collaborating hospitals either accepted central ethics approval or obtained local approval by internal ethics committees. Because of the nature of the retrospective study, the requirement of informed consent was waived.

Study Sample {#jah31324-sec-0008}
------------

Only patients with a definite discharge diagnosis of STEMI (with or without prior cardiovascular disease) were eligible for inclusion in this study. The diagnosis of STEMI was determined by the combination of clinical discharge diagnosis terms and ECG results. The type of AMI was validated by review of ECG from randomly selected records by a cardiologist not involved in data abstraction, and there was a 94.7% concordance in the selected cases (Table S1). We excluded all patients whose STEMI occurred during the course of the hospitalization and those who were transferred in, transferred out, and were discharged alive in the first 24 hours of admission (Figure S1).

Data Collection and Measures {#jah31324-sec-0009}
----------------------------

We collected data by central abstraction of medical charts with use of standardized data definitions, including patient characteristics (age, cardiovascular risk factors, clinical characteristics on presentation, and treatments) and hospital‐level characteristics (acuity level, teaching status, percutaneous coronary intervention \[PCI\] capability). We compared time from symptom onset to admission between men and women, which included both prehospital delay and time from arrival to admission. Admission was used to track the time of presentation because we lacked information about time to presentation at the hospital. We evaluated the use of treatments recommended by the 2010 National Guideline for STEMI,[18](#jah31324-bib-0018){ref-type="ref"} which are consistent with 2007 U.S. guidelines.[19](#jah31324-bib-0019){ref-type="ref"} Rates of utilization were assessed only in patients considered to be ideal for the treatment, defined as patients without accepted contraindications. Criteria identifying ideal candidates for guideline‐concordant therapies are detailed in Data S1. For the calculation of rates of diagnostic catheterization and PCI, we restricted our study group to patients admitted to facilities capable of performing PCI.

Statistical Analysis {#jah31324-sec-0010}
--------------------

To estimate nationally representative rates of hospitals admission in men and women for each study year, we applied weights proportional to the inverse sampling fraction of hospitals within each stratum and the sampling fraction of patients within each hospital, to account for differences in the sampling fraction for each period. Patient characteristics and treatments were compared between women and men, both overall and across the 3 study years (2001, 2006, and 2011). Categorical and continuous variables were summarized by percentages and medians (interquartile range), respectively, and compared using the χ^2^ tests and Student *t* tests, respectively. To examine trends across the different study periods for each sex, we used the Mann--Kendall test for continuous variables and the Cochran--Armitage test for categorical variables. We investigated the association between sex and the prevalence of cardiovascular risk factors, adjusted for age in logistic regression models. To examine the association between sex and treatment received, we also adjusted for age and other baseline characteristics as listed in Table [1](#jah31324-tbl-0001){ref-type="table-wrap"} using multivariable logistic models. We included the 2‐way interaction term sex×year in the regression model to assess whether sex differences in presenting characteristics and treatment varied by study year. All statistical analyses were performed using SAS software (version 9.2, SAS Institute, Cary, NC).

###### 

Patient Characteristics According to Sex and Study Year

  Characteristic                                                       Men, %[a](#jah31324-note-0004){ref-type="fn"}   *P* for Trends      Women, %[a](#jah31324-note-0004){ref-type="fn"}   *P* for Trends                                                                
  -------------------------------------------------------------------- ----------------------------------------------- ------------------- ------------------------------------------------- ---------------- ------------------- ------------------- -------------------- ----------
  Demographic                                                                                                                                                                                                                                                              
  Age, y[b](#jah31324-note-0005){ref-type="fn"}                        63 (53, 70)                                     64 (54, 73)         63 (53, 73)                                       0.476            68 (62, 74)         71 (65, 76)         72 (64, 78)          \<0.0001
  Cardiovascular risk factors                                                                                                                                                                                                                                              
  Hypertension                                                         38.8                                            45.9                47.3                                              \<0.0001         47.8                53.4                60.6                 \<0.0001
  Diabetes                                                             11                                              15.4                18.3                                              \<0.0001         21.1                25.8                26.9                 0.010
  Current smoker                                                       38.7                                            41.3                48                                                \<0.0001         6                   9                   11.9                 \<0.0001
  Medical history                                                                                                                                                                                                                                                          
  Coronary heart disease                                               22.6                                            19.1                20.5                                              0.355            26.2                22.2                21.8                 0.054
  Myocardial infarction                                                10.3                                            9.7                 11.6                                              0.058            9.5                 8.8                 9.3                  0.970
  PCI                                                                  0.4                                             0.9                 2.7                                               \<0.0001         0.9                 0.9                 1.5                  0.138
  Stroke                                                               9.2                                             10.3                11.5                                              0.010            10                  11.7                13.9                 0.070
  Symptom onset to admission, hour                                                                                                                                                                                                                                         
  \<6                                                                  42.2                                            40.9                41.3                                              0.467            30.9                34.1                36.9                 0.003
  6 to 12 hours                                                        8.9                                             9.6                 10.5                                              0.027            10.7                12.5                11.3                 0.921
  \>12 hours                                                           48.9                                            49.5                48.1                                              0.430            58.3                53.4                51.7                 0.008
  Clinical characteristics                                                                                                                                                                                                                                                 
  Chest discomfort                                                     93.1                                            93.2                93.4                                              0.652            91.2                89.7                89.3                 0.219
  Cardiogenic shock                                                    3.4                                             5.5                 6                                                 0.0005           6.2                 7.6                 7.9                  0.205
  Cardiac arrest                                                       0.9                                             1.3                 1.5                                               0.078            0.7                 0.8                 1.1                  0.335
  Acute stroke                                                         0.7                                             1.5                 1                                                 0.930            1.1                 2.6                 1.1                  0.318
  Heart rate ≥100 bpm[b](#jah31324-note-0005){ref-type="fn"}           15.7                                            14.8                11.6                                              \<0.0001         20.2                22.0                18.4                 0.098
  SBP ≥140 mm Hg[b](#jah31324-note-0005){ref-type="fn"}                31.3                                            31.4                32.6                                              0.256            37.3                39.3                39.7                 0.326
  LDL‐C level                                                                                                                                                                                                                                                              
  \<130                                                                35.2                                            55.8                67.6                                              \<0.0001         25.8                50.1                59.3                 \<0.0001
  ≥130                                                                 11.7                                            15.4                18.2                                              \<0.0001         12.8                18.5                22.4                 \<0.0001
  Unrecorded                                                           53.2                                            28.7                14.2                                              \<0.0001         61.3                31.4                18.3                 \<0.0001
  eGFR, mL/min per 1.73 m^2^ [b](#jah31324-note-0005){ref-type="fn"}   75.5 (60.0, 94.6)                               77.9 (61.7, 97.9)   88.1 (68.9, 109.8)                                \<0.0001         63.7 (49.1, 81.9)   66.4 (48.2, 84.2)   76.1 (55.7, 100.1)   \<0.0001
  Hospital characteristics                                                                                                                                                                                                                                                 
  Teaching hospital                                                    85                                              80.6                80.1                                              0.0001           83.5                79.7                77.8                 0.003
  PCI‐capable hospital                                                 32.8                                            55.1                72.9                                              \<0.0001         34.3                52.6                69                   \<0.0001
  Hospital with CCU                                                    81.1                                            76.3                79.4                                              0.952            78.6                77.4                78.6                 0.791
  Economic--geographic region                                                                                                                                                                                                                                              
  Central                                                              19.5                                            21                  23.2                                              \<0.0001         16.9                17.9                22                   \<0.0001
  Eastern                                                              65.7                                            58.4                54.7                                              \<0.0001         71.5                63.3                59.3                 \<0.0001
  Western                                                              14.8                                            20.6                22.1                                              \<0.0001         11.6                18.8                18.7                 \<0.0001
  Urban/rural                                                                                                                                                                                                                                                              
  Urban                                                                63.9                                            60.6                63.4                                              0.586            64                  60.9                57.9                 0.006
  Rural                                                                36.1                                            39.4                36.6                                                               36                  39.1                42.1                 

CCU indicates cardiac care unit; eGFR, estimated glomerular filtration rate; LDL‐C, low‐density lipoprotein cholesterol; PCI, percutaneous coronary intervention; SBP, systolic blood pressure.

Unless otherwise indicated.

Continuous variables displayed as median values with interquartile range.

Results {#jah31324-sec-0011}
=======

Study Sample {#jah31324-sec-0012}
------------

We sampled 18 631 cases, from which 18 110 (97.2%) had available records. We excluded 6645 cases that did not meet inclusion criteria, resulting in a study sample of 11, 986 patients with STEMI (Figure S1). There were 1364, 2541, and 4507 men (representing 29 094, 65 370, and 120 991 male patients nationally in weighted estimates) and 569, 1040, and 1965 women (representing 12 134, 27 098, and 53 585 female patients nationally in weighted estimates) in 2001, 2006, and 2011, respectively. Hospital admissions for STEMI per 100 000 people increased 4.2‐fold in men (4.6 in 2001, 10.0 in 2006, and 18.0 in 2011) and 3.9‐fold in women (1.9 in 2001, 4.1 in 2006, and 8.0 in 2011).

Patients Characteristics {#jah31324-sec-0013}
------------------------

From 2001 to 2011, the median age of patients increased from 68 to 72 years in women (*P* ~trend~\<0.001) but remained stable in men (63 years in 2011) (*P* ~trend~=0.48). The proportions of men and women aged ≥80 years old significantly increased over time (Figure [1](#jah31324-fig-0001){ref-type="fig"}). The prevalence of cardiovascular risk factors increased over time for both women and men. Women had a higher prevalence of hypertension, diabetes mellitus, and coronary heart disease in each time period (*P*\<0.001 for all comparisons) (Table [1](#jah31324-tbl-0001){ref-type="table-wrap"}). Similar findings were also found in the age‐adjusted results (Figure [2](#jah31324-fig-0002){ref-type="fig"}). In addition, sex differences in the prevalence of hypertension increased from 2001 to 2011, with women having a higher prevalence. However, sex differences in the prevalence of diabetes remained stable. Although there was no significant sex difference in those with a low‐density lipoprotein cholesterol \>130 mg/dL in 2001, this risk factor was more prevalent in women in later time periods (Figure [2](#jah31324-fig-0002){ref-type="fig"}). Women were hospitalized less often in tertiary care hospitals and hospitals with the capacity to perform PCI.

![Age distribution of the study sample according to sex and year.](JAH3-5-e002157-g001){#jah31324-fig-0001}

![Temporal trends of age‐adjusted results in sex differences in cardiovascular risk factors. LDL‐C indicates low‐density lipoprotein cholesterol; OR, odds ratio.](JAH3-5-e002157-g002){#jah31324-fig-0002}

Women were consistently were more likely to have systolic blood pressure over 140 mm Hg and heart rate over 100 bpm. Comparing 2001, 2006, and 2011, sex differences in heart rate \>100 bpm increased, yet differences in the presence of systolic blood pressure measurements did not change. Although there were significant sex differences in the time interval of \>12 hours between symptom onset and admission time in 2001, since 2006 delays in presentation were comparable between women and men (Figure [3](#jah31324-fig-0003){ref-type="fig"}). The age‐adjusted results showed that there was no sex difference in chest discomfort in 2001 and 2006, but not 2011.

![Temporal trends of age‐adjusted results in sex differences in presenting characteristics. HR indicates heart rate; OR, odds ratio; SBP, systolic blood pressure.](JAH3-5-e002157-g003){#jah31324-fig-0003}

Treatment Among Ideal Candidates {#jah31324-sec-0014}
--------------------------------

The proportion of ideal patients for aspirin, clopidogrel, β‐blocker, angiotensin‐converting enzyme inhibitor/angiotensin II receptor blocker, and statin treatments remained unchanged over time in both sex groups (Table S2). Although the proportion of women ideal for reperfusion therapy increased significantly over the last decade (from 35.7% in 2001 to 43.0% in 2011, *P* ~trend~=0.001), they remained less likely than men (48.2%) to be ideal patients for reperfusion therapy in 2011.

Overall, differences in treatment were consistently observed over the study period. The absolute differences between men and women receiving fibrinolytic therapy, primary PCI, or any reperfusion therapy were 6.7%, 5.5%, and 13.2% in 2011, respectively. In addition, any coronary angiography and nonprimary PCI were performed less commonly during initial AMI hospitalization in women in all time periods. Fewer women received aspirin or clopidogrel within 24 hours of admission (Table [2](#jah31324-tbl-0002){ref-type="table-wrap"}). After adjusting for age and other baseline characteristics, women without contraindications to treatment were significantly less likely to receive reperfusion therapy, coronary angiography, and nonprimary PCI in all time periods (Table S3). No significant sex differences were observed in the administration of other examined medications, including β‐blocker, angiotensin‐converting enzyme inhibitor/ angiotensin II receptor blocker, and statin. Between 2001 and 2011, sex differences in treatment persisted, and in some cases widened. In particular, sex differences in the utilization of primary PCI increased (Figure [4](#jah31324-fig-0004){ref-type="fig"}).

###### 

In‐Hospital Treatments Among Ideal Patients According to Sex and Year

  Characteristic                                                                                         Overall, N (%)   *P* Value     Men, %     *P* for Trends   Women, %   *P* for Trends                                   
  ------------------------------------------------------------------------------------------------------ ---------------- ------------- ---------- ---------------- ---------- ---------------- ---------- ------ ------ ------ ----------
  Acute medication                                                                                                                                                                                                              
  Aspirin ≤24 hours[a](#jah31324-note-0006){ref-type="fn"}                                               7023 (88.8)      2765 (85.9)   \<0.0001   81.1             87.7       91.8             \<0.0001   78.0   85.0   88.8   \<0.0001
  Clopidogrel ≤24 hours[a](#jah31324-note-0006){ref-type="fn"}                                           4454 (56.9)      1679 (52.5)   \<0.0001   1.4              44.3       80               \<0.0001   0.8    36.5   75.5   \<0.0001
  β‐Blockers ≤24 hours[a](#jah31324-note-0006){ref-type="fn"}                                            2371 (56.8)      770 (52.6)    0.005      47.8             62.7       56.1             0.095      46.4   54.8   53.1   0.202
  ACE‐inhibitor/ARB[a](#jah31324-note-0006){ref-type="fn"} ^,^ [b](#jah31324-note-0007){ref-type="fn"}   5073 (65.8)      1994 (63.8)   0.044      60.8             69.6       65.2             0.214      59.2   66.7   63.6   0.332
  Statin[a](#jah31324-note-0006){ref-type="fn"} ^,^ [b](#jah31324-note-0007){ref-type="fn"}              6180 (76.5)      2476 (75.1)   0.117      30.3             75.0       91.5             \<0.0001   27.8   72.6   90.4   \<0.0001
  Reperfusion therapy[b](#jah31324-note-0007){ref-type="fn"}                                                                                                                                                                    
  With reperfusion                                                                                       2289 (57.5)      646 (44.2)    \<0.0001   56.3             58.0       57.6             0.702      47.3   42.2   44.4   0.758
  Primary PCI                                                                                            757 (19.0)       203 (13.9)    \<0.0001   8.7              15.1       24.2             \<0.0001   8.4    8.9    17.7   \<0.0001
  Fibrinolytic therapy                                                                                   1535 (38.6)      443 (30.3)    \<0.0001   47.7             43.0       33.5             \<0.0001   38.9   33.3   26.8   0.0002
  Procedure[c](#jah31324-note-0008){ref-type="fn"}                                                                                                                                                                              
  Nonprimary PCI                                                                                         1117 (21.8)      299 (14.3)    \<0.0001   9.6              19.4       24.4             \<0.0001   5.6    10.2   17.1   \<0.0001
  Cardiac catheterization                                                                                2414 (47.0)      669 (31.9)    \<0.0001   34.2             41.7       51.1             \<0.0001   26.2   25.0   35.5   \<0.0001

ACE, angiotensin‐converting enzyme; ARB, angiotensin II receptor blocker; PCI, percutaneous coronary intervention.

Only among patients without contraindications for the treatment.

During hospitalization.

Only among patients admitted into a hospital capable of PCI.

![Temporal trends of sex differences in reperfusion therapy among ideal candidates. A, Primary PCI. B, Fibrinolytic therapy. C, Any reperfusion. PCI indicates percutaneous coronary intervention.](JAH3-5-e002157-g004){#jah31324-fig-0004}

Discussion {#jah31324-sec-0015}
==========

In this large, national study in China of hospitalization for STEMI, we found marked sex differences in clinical profiles and quality of care. Women, who experienced a slightly higher increase (4.2‐fold versus 3.9‐fold) in STEMI over the study period, were older, had greater comorbidities, and were less likely to be ideal patients for many evidence‐based therapies. Among ideal patients, women were significantly less likely to receive a revascularization strategy (including fibrinolysis or cardiac catheterization with or without PCI), even after accounting for differences in clinical profiles. These sex‐based differences in patient characteristics and hospital care did not change significantly over the past decade, underscoring the need to specifically address these findings with quality improvement efforts.

We had previously shown in the China PEACE study that the risk of mortality was age dependent and most pronounced among younger women (\<70 years of age) with STEMI, even after accounting for differences in clinical presentation and treatments.[3](#jah31324-bib-0003){ref-type="ref"} However, we had not investigated temporal trends in sex differences as they relate to patient characteristics and receipt of evidence‐based therapies in STEMI. We found that even after adjusting for age, with the exception of smoking, a predominantly male activity in China,[20](#jah31324-bib-0020){ref-type="ref"} risk factors including greater age, diabetes, hypertension, and dyslipidemia were more common in women presenting with STEMI. These are consistent with prior national and international studies.[21](#jah31324-bib-0021){ref-type="ref"}, [22](#jah31324-bib-0022){ref-type="ref"}

The clinical presentation of women differed from men. Indeed, half of the women in our study presented outside the time window for reperfusion therapy, which is consistent over the last decade. However, we did observe a decrease in the delay to admission among women, and sex differences in the time interval of \>12 hours between symptom onset and admission time disappeared since 2006, which might partly be due to improved healthcare accessibility for women in China.[23](#jah31324-bib-0023){ref-type="ref"}

While the quality of care improved for both men and women, significant sex gaps exist and have not improved over time. Significantly fewer women received a reperfusion strategy, even when they presented promptly for treatment. Additionally, among patients deemed to be ideal candidates, women were less likely than men to receive aspirin and clopidogrel. Sex differences in treatment response have not been supported by the literature; rather, prior studies indicate that both women and men derive similar reductions in morbidity and mortality with the prescriptions of aspirin, clopidogrel, and with invasive cardiac procedures,[4](#jah31324-bib-0004){ref-type="ref"} and guidelines do not recommend differential use of these therapies based upon sex. The disparities in care identified in this study require full‐scale investigation into clinical decision‐making and targeted efforts to diminish such disparities.

The rising burden of modifiable cardiovascular risk factors among women will require local and national efforts to advance primary and secondary prevention strategies; such efforts may need to directly target women at high risk of heart attack. The marked underutilization of coronary catheterization and reperfusion therapy should prompt quality improvement efforts to ensure that the evidence‐based management of STEMI is rigorously applied in patients of both sexes.[24](#jah31324-bib-0024){ref-type="ref"} In the interim, large‐scale educational initiatives targeting women should be implemented in both pre‐hospital and in‐hospital settings to increase women\'s and their health providers' awareness of cardiovascular disease and recognition of symptoms of AMI,[25](#jah31324-bib-0025){ref-type="ref"}which has been proven to be effective in the Go Red for Women campaign, which was initiated in the United States.[25](#jah31324-bib-0025){ref-type="ref"} Ultimately, dispelling myths (or old assumptions) and improving awareness is difficult and will require innovative, multipronged efforts.

Limitations {#jah31324-sec-0016}
-----------

The results of our study should be interpreted with consideration of several limitations. First, residual confounding of measured or unmeasured variables might affect the observed results. However, we accounted for traditional clinical factors common among risk models predicting early mortality. Second, given that relatively few patients underwent a cardiac catheterization, we were not able to adjust our analysis to account for the severity and extent of coronary artery diseases that might contribute to the sex differences in mortality.[26](#jah31324-bib-0026){ref-type="ref"} However, these data are not typically included in risk‐adjusted models, and it is not clear that anatomy would affect in‐hospital mortality differently in men and women.

Conclusions {#jah31324-sec-0017}
===========

In a large, nationally representative observational study in China, women hospitalized with STEMI were older, had greater delays in care seeking, more comorbidities, and worse disease severity than men. Moreover, women were less likely to be candidates for, and less likely to receive, evidence‐based therapies as compared with men. These disparities have changed little over the past decade despite large‐scale efforts to increase access and quality. These findings underscore the need for improved systems to ensure the prompt diagnosis and use of evidence‐based treatments for women with STEMI, particularly with respect to reperfusion therapies.
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